- Company
- Suhee Shin appointed new General Manager of Amgen Korea
- by Eo, Yun-Ho Jun 19, 2024 05:46am
- Suhee Shin, the former head of Novartis Korea, is coming back to head another Korean subsidiary of a multinational pharmaceutical company after two and a half years. According to industry sources, Director Suhee Shin, who had been leading the Healthcare Innovation Cluster at Roche Korea, has been appointed to take over as the General Mana
- Company
- New multiple sclerosis drug Ocrevus is approved in Korea
- by Son, Hyung-Min Jun 19, 2024 05:46am
- A new drug for multiple sclerosis (MS), an intractable disease characterized by a high relapse rate, has been introduced to the market. Roche's Ocrevus was approved in Korea for the treatment of relapsing-remitting MS as well as primary progressive MS, for which there had been no treatment options available. Medical experts have expressed
- Company
- "Novotech is a global CRO partner for Korean biotech"
- by Lee, Tak-Sun Jun 19, 2024 05:46am
- Novotech is a global full-service clinical Contact Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of innovative and novel therapies at every clinical phase. Recognized for its CRO industry-leading contributions, Novotech received numerous prestigious awards, including the CRO Leadership
- Company
- Lucentis biosimilars occupy 16% of mkt in 1 year
- by Chon, Seung-Hyun Jun 19, 2024 05:46am
- The market size for the eye disease drug Lucentis has shrunk significantly. Last year, its biosimilars entered the market and reduced the drug price of Lucentis, reducing the market size. Although the market share of the two biosimilars remains a mere 16%, the price reduction of Lucentis saved more than KRW 10 billion in annual health insurance
- Company
- Targeted therapies for HER2m NSCLC actively developed
- by Son, Hyung-Min Jun 18, 2024 05:49am
- The domestic and foreign pharmaceutical industry has taken up the challenge of developing a new drug for HER2-positive NSCLC. After Enhertu opened the door by obtaining the first marketing authorization as an anticancer drug targeting the HER2 mutation in Korea, many later entrants such as Yuhan Corp, Boehringer Ingelheim, and Hanmi Pharmaceutic
- Policy
- "People do not recognize generic equivalence"…
- by Lee, Hye-Kyung Jun 18, 2024 05:48am
- "80% of the medicines approved in Korea are generics, which account for 53% of medical expenses. However, consumer perception of generics’ equivalence to original medicines remains at 50%. The Ministry of Food and Drug Safety (MFDS) should be concerned and ashamed of this outcome." Lee Eui-Kyung, a professor at the School of Pharmacy at Sung
- Policy
- Ceprotin Inj passes reimbursement committee’s review
- by Lee, Tak-Sun Jun 18, 2024 05:48am
- The congenital protein C deficiency treatment ‘Ceprotin Inj’ was recognized as adequate for reimbursement by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC). As a result, its final reimbursement will be determined through pricing negotiations with the National Health Insurance Service.
- Company
- Eisai’s JAK inhibitor, 'Jyseleca,' has landed at hospitals
- by Eo, Yun-Ho Jun 18, 2024 05:48am
- Eisai Korea’s 'Jyseleca,' a JAK inhibitor, is now available for prescription at general hospitals in South Korea. According to industry sources, Jyseleca, which is the fifth JAK inhibitor in South Korea, has passed the drug committee (DC) of Big 5 tertiary general hospitals, including Seoul National University, Seoul Asan Hospital, an
- Policy
- Fasenra·Xpovio reimb from July…Jardiance price cut
- by Lee, Tak-Sun Jun 18, 2024 05:47am
- The severe asthma treatment Fasenra Prefilled Syringe 30 mg (benralizumab, AZ) and multiple myeloma treatment Xpovio Tab 20 mg (selinexor, Antengene) may be reimbursed as early as July. The companies that own the two products have completed drug pricing negotiations with the National Health Insurance Service, and are waiting for them to
- Company
- Noh will retire from Amgen after 9 years since its inception
- by Eo, Yun-Ho Jun 17, 2024 05:46am
- Noh Sang-kyung (61), general manger of Amgen Korea, who led Amgen’s Korean office since its inception is set to retire from the company. According to industry sources, Noh has recently confirmed his retirement from the company. He has served in this role for nine years since the company’s inception in South Korea in 2015. His succe
